Acurx Pharmaceuticals Valuation
Is ACXP undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
2/6Valuation Score 2/6
Unter dem Marktwert
Deutlich unter dem Marktwert
Price-To-Book gegen Gleichaltrige
Price-To-Book gegen Industrie
PM vs. Fair Ratio
Analysten-Prognose
Share Price vs Fair Value
What is the Fair Price of ACXP when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Unter dem Marktwert: Unzureichende Daten zur Berechnung des beizulegenden Zeitwerts von ACXP für die Bewertungsanalyse.
Deutlich unter dem Marktwert: Unzureichende Daten zur Berechnung des beizulegenden Zeitwerts von ACXP für die Bewertungsanalyse.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for ACXP?
Other financial metrics that can be useful for relative valuation.
| What is ACXP's n/a Ratio? | |
|---|---|
| n/a | 0x |
| n/a | n/a |
| Market Cap | US$31.51m |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | n/a |
| Enterprise Value/EBITDA | n/a |
| PEG Ratio | n/a |
Price to Book Ratio vs Peers
How does ACXP's PB Ratio compare to its peers?
| Company | Forward PB | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 18.5x | ||
MRKR Marker Therapeutics | 2.9x | n/a | US$40.5m |
AURX Nuo Therapeutics | 59.7x | n/a | US$43.4m |
CYTH Cyclo Therapeutics | 8.2x | 63.8% | US$39.1m |
VIRX Viracta Therapeutics | 3.3x | 22.1% | US$42.8m |
ACXP Acurx Pharmaceuticals | 6.8x | 7.4% | US$31.5m |
Price-To-Book gegen Gleichaltrige: ACXP ist ein guter Wert, wenn man sein Price-To-Book Verhältnis (6.6x) mit dem Durchschnitt der anderen Unternehmen (254.3x) vergleicht.
Price to Earnings Ratio vs Industry
How does ACXP's PE Ratio compare vs other companies in the US Biotechs Industry?
Price-To-Book gegen Industrie: ACXP ist teuer, wenn man sein Price-To-Book Verhältnis (10.3x) mit dem US Biotechs Branchendurchschnitt (2.1x) vergleicht.
Price to Book Ratio vs Fair Ratio
What is ACXP's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PB Ratio | 6.8x |
| Fair PB Ratio | n/a |
PM vs. Fair Ratio: Unzureichende Daten zur Berechnung der Price-To-Book Fair Ratio von ACXP für die Bewertungsanalyse.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
| Date | Share Price | Average 1Y Price Target | Dispersion | High | Low | 1Y Actual price | Analysts |
|---|---|---|---|---|---|---|---|
| Current | US$2.00 | US$11.45 +472.5% | 9.0% | US$12.35 | US$10.00 | n/a | 3 |
| Mar ’25 | US$2.96 | US$12.12 +309.3% | 13.5% | US$14.00 | US$10.00 | n/a | 3 |
| Feb ’25 | US$3.26 | US$12.59 +286.1% | 13.0% | US$14.00 | US$10.00 | n/a | 4 |
| Jan ’25 | US$3.83 | US$12.67 +230.7% | 14.9% | US$14.00 | US$10.00 | n/a | 3 |
| Dec ’24 | US$3.79 | US$12.33 +225.4% | 13.8% | US$14.00 | US$10.00 | n/a | 3 |
| Nov ’24 | US$5.07 | US$12.33 +143.3% | 13.8% | US$14.00 | US$10.00 | n/a | 3 |
| Oct ’24 | US$1.50 | US$11.33 +655.6% | 27.3% | US$14.00 | US$7.00 | n/a | 3 |
| Sep ’24 | US$1.85 | US$11.33 +512.6% | 27.3% | US$14.00 | US$7.00 | n/a | 3 |
| Aug ’24 | US$1.98 | US$13.33 +573.4% | 7.1% | US$14.00 | US$12.00 | n/a | 3 |
| Jul ’24 | US$2.65 | US$13.33 +403.1% | 7.1% | US$14.00 | US$12.00 | n/a | 3 |
| Jun ’24 | US$2.95 | US$13.33 +352.0% | 7.1% | US$14.00 | US$12.00 | n/a | 3 |
| May ’24 | US$2.95 | US$13.33 +352.0% | 7.1% | US$14.00 | US$12.00 | n/a | 3 |
| Apr ’24 | US$3.46 | US$13.33 +285.4% | 7.1% | US$14.00 | US$12.00 | US$2.28 | 3 |
| Mar ’24 | US$3.30 | US$13.33 +304.0% | 7.1% | US$14.00 | US$12.00 | US$2.96 | 3 |
| Feb ’24 | US$3.56 | US$13.33 +274.5% | 7.1% | US$14.00 | US$12.00 | US$3.26 | 3 |
| Jan ’24 | US$3.98 | US$13.33 +235.0% | 7.1% | US$14.00 | US$12.00 | US$3.83 | 3 |
| Dec ’23 | US$3.13 | US$13.00 +315.3% | 7.7% | US$14.00 | US$12.00 | US$3.79 | 2 |
Analysten-Prognose: Das Kursziel liegt mehr als 20% über dem aktuellen Aktienkurs, und die Analysten liegen in einem statistisch sicheren Bereich der Übereinstimmung.